The benefits of an ALCAR supplement over an L-carnitine product relates to its bioavailability
Saxenda FDA Approval and Its Black Box Warning Saxenda received FDA approval on December 23, 2014, for weight loss management in adults with obesity or who are overweight (BMI of 27 kg/m or higher) with at least one weight-related medical condition
Retatrutide NAFLD - Phase 2 Trial Results in Subset of Patients with Obesity and NAFLD
Those experiencing unexplained symptoms, skin reactions, or signs of hypoglycaemia (dizziness, sweating, confusion) should seek prompt medical attention
Brain Research 1036, 1-6CrossRefGoogle ScholarPubMed 94Sagara, J., Miura, K
Among those seeking obesity treatment, 1.4% to 9% meet DSM criteria for BED (Allison et al., 2007